Introduction Criteria for mild cognitive impairment (MCI) used in many clinical trials are susceptible to "false-positive (FP)" errors that can be avoided by an actuarial psychometric approach. Methods Cluster analysis was applied to baseline neuropsychological test data from 756 MCI participants in the Alzheimer's Disease Cooperative Study donepezil trial. Treatment groups were compared afte...

The prognosis of glioblastoma (GBM) remains poor. Diffuse invasion of distant brain tissue by migrating cells from the primary tumour mass has already occurred at time of diagnosis. Anti-cancer effects of a selective sigma-1 agonist, 4-(N-benzylpiperidin-4-yl)-4-iodobenzamide (4-IBP), in glioblastoma were shown previously, leading to the present work where the effects on glioblastoma cells of 1...

Study selection and analysis: Eligible studies were randomised controlled trials comparing donepezil versus placebo in people with mild to moderate Alzheimer’s disease (MMSE criteria). Trials were undertaken and completed by 20 December 1999. Exclusions: not stated. Data were extracted for each individual study on the efficacy and safety of donepezil. Meta-analysis was carried out using fixed a...

A sensitive, isocratic reversed-phase high performance liquid chromatographic method involving fluorescence detection was developed for the determination of donepezil hydrochloride in tablets and in human plasma. Pindolol was used as an internal standard. Good chromatographic separation was achieved by using an analytical column C18. The system operated at room temperature using a mobile phase ...

A 67-year-old woman with Alzheimer’s disease was administered 5 mg/day donepezil for approximately three years. The patient exhibited acute confusion, global impairment of cognition with disorientation, sleep disturbance, psychomotor agitation, hallucinations and delusions due to delirium at night. She was then administered 8 mg/day blonanserin for approximately one month in addition to donepez...

Neurodegenerative diseases are incurable and debilitating conditions that result in progressive degeneration and/or death of nerve cells. This causes problems with movement (called ataxis), or mental functioning (called dementia). Alzheimer’s is a chronic neurodegenerative disease of the brain that causes problems with memory, thinking and behavior. It is not a normal part of aging. The cause o...

A stability indicating HPLC method for the estimation of donepezil hydrochloride in tablets was developed and validated. Donepezil hydrochloride is a reversible inhibitor of acetylcholinesterase, indicated for the treatment of mild to moderate dementia of the Alzheimer’s type. The HPLC method was performed with a reversed phase C18 column (250 mm X 4.6 mm id, 5mm particle size), detection at 23...

Alzheimer's disease (AD) is the most common type of senile dementia, characterized by cognitive deficits related to degeneration of cholinergic neurons. The first anti-Alzheimer drugs approved by the Food and Drug Administration were the cholinesterase inhibitors (ChEIs), which are capable of improving cholinergic neurotransmission by inhibiting acetylcholinesterase. The most common ChEIs used ...